About Biocept (NASDAQ:BIOC)
Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients who have been diagnosed with cancer based on molecular drivers. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BIOC
CUSIPN/A
Phone858-320-8200
Debt
Debt-to-Equity Ratio0.89%
Current Ratio0.91%
Quick Ratio0.81%
Price-To-Earnings
Trailing P/E Ratio-0.32
Forward P/E Ratio-0.86
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.07 million
Price / Sales3.22
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book12.00
Profitability
EPS (Most Recent Fiscal Year)($0.79)
Net Income$-21,610,000.00
Net Margins-426.48%
Return on Equity-374.92%
Return on Assets-169.29%
Miscellaneous
Employees95
Outstanding Shares68,040,000
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept (NASDAQ:BIOC) issued its earnings results on Wednesday, March, 28th. The medical research company reported ($0.18) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.16) by $0.02. The medical research company earned $1 million during the quarter, compared to analysts' expectations of $1.23 million. Biocept had a negative net margin of 426.48% and a negative return on equity of 374.92%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
2 equities research analysts have issued twelve-month target prices for Biocept's shares. Their predictions range from $1.00 to $1.50. On average, they anticipate Biocept's share price to reach $1.25 in the next year. View Analyst Ratings for Biocept.
Who are some of Biocept's key competitors?
Some companies that are related to Biocept include ReWalk Robotics (RWLK), Actinium Pharmaceuticals (ATNM), Streamline Health Solutions (STRM), Vical (VICL), Cleveland BioLabs (CBLI), Surgical Innovations (SUN), OvaScience (OVAS), Cancer Genetics (CGIX), Kitov Pharma (KTOV), Pernix Therapeutics (PTX), Digirad (DRAD), Jaguar Health (JAGX), Innovus Pharmaceuticals (INNV), Tonix Pharmaceuticals (TNXP), AEterna Zentaris (AEZS), Concordia International (CXRX), Interpace Diagnostics Gr (IDXG) and AIT Therapeutics (AITB).
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 55)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer & Member of Scientific Advisory Board (Age 71)
- Dr. Veena M. Singh, Sr. VP, Sr. Medical Director & Member of Scientific Advisory Board (Age 43)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations, Sec. & Principal Accounting Officer (Age 60)
Has Biocept been receiving favorable news coverage?
Headlines about BIOC stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Biocept earned a news sentiment score of 0.16 on Accern's scale. They also assigned media coverage about the medical research company an impact score of 44.73 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $0.24.
How big of a company is Biocept?
Biocept has a market capitalization of $16.57 million and generates $5.07 million in revenue each year. The medical research company earns $-21,610,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Biocept employs 95 workers across the globe.
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biocept (NASDAQ:BIOC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for Biocept in the last 12 months. Their average twelve-month price target is $1.25, suggesting that the stock has a possible upside of 420.83%. The high price target for BIOC is $1.50 and the low price target for BIOC is $1.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $1.25 | $1.50 | $2.25 | $2.50 |
| Price Target Upside: | 420.83% upside | 134.38% upside | 251.56% upside | 78.57% upside |
Biocept (NASDAQ:BIOC) Consensus Price Target History
Biocept (NASDAQ:BIOC) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
Biocept (NASDAQ:BIOC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Biocept (NASDAQ BIOC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.70%
Institutional Ownership Percentage: 8.68%
Biocept (NASDAQ BIOC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 10/19/2016 | Claire Reiss | Major Shareholder | Buy | 227,272 | $1.10 | $249,999.20 | |  |
| 10/19/2016 | David F. Hale | Director | Buy | 90,909 | $1.10 | $99,999.90 | | |
| 10/19/2016 | Lyle J. Arnold | SVP | Buy | 45,000 | $1.10 | $49,500.00 | | |
| 10/19/2016 | Timothy Kennedy | CFO | Buy | 36,363 | $1.10 | $39,999.30 | | |
| 5/4/2016 | Bruce Gerhardt | Director | Buy | 25,000 | $1.00 | $25,000.00 | 58,985 | |
| 5/4/2016 | Claire Reiss | Major Shareholder | Buy | 614,273 | $1.00 | $614,273.00 | | |
| 2/13/2015 | David F Hale | Chairman | Buy | 40,000 | $1.25 | $50,000.00 | | |
| 2/13/2015 | Marsha Alpert Chandler | Director | Buy | 2,000 | $1.25 | $2,500.00 | | |
| 2/13/2015 | Michael W Nall | CEO | Buy | 12,000 | $1.25 | $15,000.00 | | |
(Data available from 1/1/2013 forward)
Biocept (NASDAQ BIOC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Critical Survey: Biocept (BIOC) and Genomic Health (GHDX)
www.americanbankingnews.com - April 21 at 7:36 PM |
| Biocept (BIOC) and Its Competitors Critical Analysis
www.americanbankingnews.com - April 21 at 9:18 AM |
| Reviewing Biocept (BIOC) and Its Competitors
www.americanbankingnews.com - April 21 at 9:18 AM |
| Biocept (BIOC) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 18 at 7:30 PM |
| Biocept (BIOC) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 17 at 7:34 PM |
| Critical Comparison: Biocept (BIOC) versus The Competition
www.americanbankingnews.com - April 15 at 5:15 PM |
| Miragen Therapeutics (MGEN) and Biocept (BIOC) Head to Head Survey
www.americanbankingnews.com - April 12 at 11:19 PM |
| Westpark Capital Reaffirms Outperform Rating for Biocept (BIOC)
www.americanbankingnews.com - April 12 at 9:35 PM |
| Comparing Biocept (BIOC) & Its Competitors
www.americanbankingnews.com - April 12 at 5:27 PM |
| Zacks: Analysts Expect Biocept (BIOC) to Announce -$0.07 EPS
www.americanbankingnews.com - April 8 at 7:28 AM |
 | Biocept to Webcast Presentation at the 7th Annual MicroCap Conference
finance.yahoo.com - April 6 at 8:18 AM |
| Free Post Earnings Research Report: Exact Sciences’ Quarterly Revenues Jumped 148.02%
finance.yahoo.com - April 6 at 8:18 AM |
| Biocept (BIOC) vs. The Competition Head to Head Contrast
www.americanbankingnews.com - April 5 at 3:03 PM |
| Biocept (BIOC) Given "Outperform" Rating at Westpark Capital
www.americanbankingnews.com - April 4 at 11:55 AM |
| Critical Contrast: Biocept (BIOC) & Its Rivals
www.americanbankingnews.com - April 4 at 5:15 AM |
| Contrasting Biocept (BIOC) and Its Competitors
www.americanbankingnews.com - April 3 at 1:26 PM |
| Biocept to Present at the 7th Annual MicroCap Conference
finance.yahoo.com - April 3 at 8:15 AM |
 | Biocept's (BIOC) CEO Michael Nall on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 29 at 8:19 AM |
| Biocept Obtains Patent for its Target Selector Molecular Biomarker Technology in China
finance.yahoo.com - March 29 at 8:19 AM |
| Biocept (BIOC) Posts Earnings Results, Misses Expectations By $0.02 EPS
www.americanbankingnews.com - March 29 at 7:38 AM |
| Biocept Reports 2017 Fourth Quarter and Full Year Financial Results
finance.yahoo.com - March 28 at 5:24 PM |
 | Biocept (BIOC), Thermo Fisher Scientific Enter into Technology and Commercial Collaboration
www.streetinsider.com - March 28 at 8:22 AM |
 | BRIEF-Biocept And Thermo Fisher Scientific Enter Into Technology And Commercial Collaboration
www.reuters.com - March 28 at 8:22 AM |
| Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration
finance.yahoo.com - March 28 at 8:22 AM |
| Comparing Biocept (BIOC) & Kindred Healthcare (KND)
www.americanbankingnews.com - March 24 at 1:18 AM |
| OmniComm Systems (OMCM) and Biocept (BIOC) Critical Analysis
www.americanbankingnews.com - March 22 at 1:38 PM |
 | Biocept to Present Recent Advances in Biomarker Identification from ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:41 AM |
| Biocept (BIOC) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 21 at 1:56 AM |
| Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio's 11th Biomarker Summit
finance.yahoo.com - March 20 at 8:20 AM |
| Head to Head Comparison: Biocept (BIOC) vs. Streamline Health Solutions (STRM)
www.americanbankingnews.com - March 17 at 5:14 PM |
| Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer ... - PR Newswire (press release)
www.prnewswire.com - March 16 at 8:13 AM |
| Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 15 at 8:10 AM |
| Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March ... - PR Newswire (press release)
www.prnewswire.com - March 12 at 8:29 AM |
| Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2018
finance.yahoo.com - March 12 at 8:29 AM |
| Biocept to Present at the 30th Annual ROTH Conference
finance.yahoo.com - March 6 at 5:44 PM |
| Short Interest in Biocept Inc (BIOC) Increases By 52.8%
www.americanbankingnews.com - March 3 at 3:26 AM |
| Biocept (BIOC) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - February 26 at 3:20 AM |
| Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform
finance.yahoo.com - February 5 at 8:58 AM |
| Dawson James Securities Announces Closing of Approximately $14.78M Public Offering for Biocept, Inc.
finance.yahoo.com - February 1 at 9:10 AM |
| Biocept Comments on Updated Consensus Medical Guidelines Recommending Liquid Biopsy for Profiling of Tumor Biomarkers to Assist with the Treatment of Patients with Lung Cancer
finance.yahoo.com - January 30 at 8:47 AM |
 | Technical Perspectives on Medical Research Stocks -- Accelerate Diagnostics, Biocept, Exact Sciences, and HTG Molecular Diagnostics
www.bizjournals.com - January 29 at 9:10 AM |
| Biocept Announces Pricing of $15.0 Million Public Offering of 33333333 Shares of Common Stock and Warrants to ... - PR Newswire (press release)
www.prnewswire.com - January 27 at 3:42 PM |
| Biocept Inc (BIOC) Dilutes Shareholders a Second Time in Two Months
finance.yahoo.com - January 26 at 3:39 PM |
| BRIEF-Biocept Prices $15 Million Public Offering Of 33.3 Mln Shares and Warrants
www.reuters.com - January 26 at 8:43 AM |
| Biocept Announces Pricing of $15.0 Million Public Offering of 33,333,333 Shares of Common Stock and Warrants to Purchase 33,333,333 Shares of Common Stock
finance.yahoo.com - January 26 at 8:43 AM |
| Zacks Investment Research Lowers Biocept (BIOC) to Hold
www.americanbankingnews.com - January 18 at 6:10 PM |
| Scientists seek super-shot for flu 100 years after pandemic
finance.yahoo.com - January 17 at 3:38 PM |
| Biocept (BIOC) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 15 at 7:28 PM |
| Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers
finance.yahoo.com - January 9 at 11:10 AM |
| Biocept Obtains Patent in Australia for its Molecular Biomarker ... - PR Newswire (press release)
www.prnewswire.com - January 5 at 11:42 AM |
Biocept (NASDAQ:BIOC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Biocept (NASDAQ:BIOC) Income Statement, Balance Sheet and Cash Flow Statement
Biocept (NASDAQ BIOC) Stock Chart for Monday, April, 23, 2018
Loading chart…
